News
06-04-2010, 06:40 AM
Bayer HealthCare will present a combined analysis from Phase I and II clinical trials evaluating the safety and efficacy of one of its lead investigational cancer treatments, Alpharadin™ (radium-223 chloride), in castration-resistant prostate cancer (CRPC) that has spread to the bones (metastases).
More... (http://www.news-medical.net/news/20100604/Bayer-to-present-Phase-I-and-II-clinical-trial-data-of-Alpharadin-in-CRPC-at-46th-ASCO.aspx)
More... (http://www.news-medical.net/news/20100604/Bayer-to-present-Phase-I-and-II-clinical-trial-data-of-Alpharadin-in-CRPC-at-46th-ASCO.aspx)